ANC-501 Clinical trial

EmbarkNeuro is conducting a first of its kind precision medicine study of ANC-501 in patients with Major Depression, who have biomarker-confirmed disruptions in their bodies stress hormone system. Study participants will take an experimental medicine for 8 weeks while tracking their symptoms and day to day activities. The total duration of participation is 16 weeks including the follow-up period. Learn more about the trial.